July 22, 2025
A large real-world comparative analysis presented at ECOP 2024 assessed nearly 3,700 patients with metastatic castration-sensitive prostate cancer (mCSPC) using U.S. electronic health records collected from December 2018 through December 2023. The study demonstrated a significant overall survival benefit for patients treated with Erleada (apalutamide) compared to Xtandi (enzalutamide). Specifically, patients receiving Erleada showed an impressive 24-month overall survival rate of 87.6%, compared to 84.6% for those receiving Xtandi, representing a relative risk reduction of death of 23%. These robust findings align closely with earlier randomized controlled trials and reinforce Erleada’s efficacy in routine clinical practice, where patient populations and conditions can vary substantially. This substantial real-world evidence highlights the practical superiority of Erleada, providing critical insights for clinicians seeking optimal therapeutic outcomes in managing mCSPC patients.
Citation: Cure Today, 2024. Available at: https://www.curetoday.com/view/erleada-may-be-a-new-standard-of-care-for-some-with-prostate-cancer
Implication: Real-world evidence supporting superior survival may shift clinical preferences toward Erleada in managing mCSPC.